NL-OMON51955招募中4 期
rEaL-world pharmacokinetics of Immune Checkpoint InhibiTors (ELICIT) - ELICIT
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Treatment with the ICIs mentioned in paragraph 4.1
- •- Willingness and ability to provide written IC
- •- Age 18 years or older
排除标准
- •Since we aim to assess the real-world pharmacokinetics, we will not make use of
- •any exclusion criteria.
研究者
相似试验
进行中（未招募）
1 期
The course of blood concentrations of immunotherapy during and after treatmentEUCTR2021-001509-66-NLRadboud University Medical Center140
终止
不适用
Real World Pharmacokinetics of Immune Checkpoint InhibitorsCancerNCT04833075Radboud University Medical Center19
招募中
Unknown
A real-world study of efficacy and safety of Immune check point inhibitors in patients with non-small cell lung cancer harboring driver oncogene excepting EGFRJPRN-UMIN000049022orth East Japan Study Group870
招募中
不适用
Predictive biomarker study of immune checkpoint inhibitors in metastatic head and neck squamous cell carcinomaNeoplasmsKCT0007598ational Cancer Center50
招募中
不适用
Real-world Efficacy and Safety of Immune check point inhibitors for Refractory Head and Neck Cancer: A Retrospective Multicenter StudyNeoplasmsKCT0004258Chung-Ang Univerisity Hospital100